{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:17:59Z","timestamp":1707524279248},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,26]]},"DOI":"10.7759\/cureus.17466","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T16:22:19Z","timestamp":1629994939000},"source":"Crossref","is-referenced-by-count":1,"title":["5q Deletion Myelodysplastic Syndrome in a Young Male Patient"],"prefix":"10.7759","author":[{"given":"Sherif","family":"Elkattawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Ayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"El-Feki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xutong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Appiah-Kubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afrah","family":"Talpur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094912","article-title":"What lies beyond del(5q) in myelodysplastic syndrome?","volume":"98","author":"Adema V","year":"2013","unstructured":"Adema V, Bejar R. What lies beyond del(5q) in myelodysplastic syndrome?. Haematologica. 2013, 98:1819-21. 10.3324\/haematol.2013.094912","journal-title":"Haematologica"},{"key":"ref2","unstructured":"5q minus syndrome. (2015). Accessed. July 10, 2021: https:\/\/medlineplus.gov\/genetics\/condition\/5q-minus-syndrome\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2022-3","article-title":"Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide","volume":"93","author":"Gaballa MR","year":"2014","unstructured":"Gaballa MR, Besa EC. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. Ann Hematol. 2014, 93:723-33. 10.1007\/s00277-014-2022-3","journal-title":"Ann Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13207","article-title":"Molecular pathogenesis of myelodysplastic syndromes with deletion 5q","volume":"102","author":"Lee JH","year":"2019","unstructured":"Lee JH, List A, Sallman D. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q. Eur J Haematol. 2019, 102:203-209. 10.1111\/ejh.13207","journal-title":"Eur J Haematol"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.4103\/0377-4929.208396","article-title":"5q deletion myelodysplastic syndrome","volume":"60","author":"Chari PS","year":"2017","unstructured":"Chari PS, Chander S, Sundareshan TS, Prasad S. 5q deletion myelodysplastic syndrome. Indian J Pathol Microbiol. 2017, 60:301-3.","journal-title":"Indian J Pathol Microbiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2015.037","article-title":"Recent advances in the 5q- syndrome","volume":"7","author":"Pellagatti A","year":"2015","unstructured":"Pellagatti A, Boultwood J. Recent advances in the 5q- syndrome. Mediterr J Hematol Infect Dis. 2015, 7:e2015037. 10.4084\/MJHID.2015.037","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.248955","article-title":"Myelodysplastic syndromes: moving towards personalized management","volume":"105","author":"Hellstr\u00f6m-Lindberg E","year":"2020","unstructured":"Hellstr\u00f6m-Lindberg E, Tobiasson M, Greenberg P. Myelodysplastic syndromes: moving towards personalized management. Haematologica. 2020, 105:1765-1779. 10.3324\/haematol.2020.248955","journal-title":"Haematologica"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V36.5.590.590","article-title":"Erythropoietin and the regulation of erythropoiesis in DiGuglielmo's syndrome","volume":"36","author":"Adamson JW","year":"1970","unstructured":"Adamson JW, Finch CA. Erythropoietin and the regulation of erythropoiesis in DiGuglielmo's syndrome. Blood. 1970, 36:590-597. 10.1182\/blood.V36.5.590.590","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.09.002","article-title":"Erythroleukemia-historical perspectives and recent advances in diagnosis and management","volume":"32","author":"Boddu P","year":"2018","unstructured":"Boddu P, Benton CB, Wang W, Borthakur G, Khoury JD, Pemmaraju N. Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev. 2018, 32:96-105. 10.1016\/j.blre.2017.09.002","journal-title":"Blood Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0085-4","article-title":"Myelodysplastic syndromes current treatment algorithm 2018","volume":"8","author":"Steensma DP","year":"2018","unstructured":"Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018, 8:47. 10.1038\/s41408-018-0085-4","journal-title":"Blood Cancer J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.063420","article-title":"Infections in myelodysplastic syndromes","volume":"97","author":"Toma A","year":"2012","unstructured":"Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. Haematologica. 2012, 97:1459-70. 10.3324\/haematol.2012.063420","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.33696\/immunology.2.049","article-title":"Cyclosporine broadens the therapeutic potential of lenalidomide in myeloid malignancies","volume":"2","author":"Dou A","year":"2020","unstructured":"Dou A, Fang J. Cyclosporine broadens the therapeutic potential of lenalidomide in myeloid malignancies. J Cell Immunol. 2020, 2:237-44. 10.33696\/immunology.2.049","journal-title":"J Cell Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18477","article-title":"Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy","volume":"8","author":"Prebet T","year":"2017","unstructured":"Prebet T, Cluzeau T, Park S, et al.. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. Oncotarget. 2017, 8:81926-35. 10.18632\/oncotarget.18477","journal-title":"Oncotarget"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/63151-5q-deletion-myelodysplastic-syndrome-in-a-young-male-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:35Z","timestamp":1707507275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/63151-5q-deletion-myelodysplastic-syndrome-in-a-young-male-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.17466","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,26]]}}}